BenevolentAI unites technology with human intelligence to re-engineer drug discovery and deliver life-changing medicines. We have developed the Benevolent PlatformВ®, a drug discovery platform built on powerful data foundations with state of the art machine learning and AI technology. Our technology empowers scientists to decipher the vast and complex code underlying human biology, find new ways to treat disease and personalise medicines to patients. Benevolent has active in-house R&D drug programmes in disease areas such as neurodegeneration, immunology, oncology and inflammation and has research and commercial collaborations with leading pharmaceutical and research organisations. The company is headquartered in London with a research facility in Cambridge (UK) and a further office in New York.